Chemotherapy-induced peripheral neuropathy

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is common in patients receiving anticancer treatment and can affect survivability and long-term quality of life of the patient following treatment. The symptoms of CIPN primarily include abnormal sensory discrimination of touch, vibration, thermal information, and pain. There is currently a paucity of pharmacological agents to prevent or treat CIPN. The lack of efficacious therapeutics is due, at least in part, to an incomplete understanding of the mechanisms by which chemotherapies alter the sensitivity of sensory neurons. Although the clinical presentation of CIPN can be similar with the various classes of chemotherapeutic agents, there are subtle differences, suggesting that each class of drugs might induce neuropathy via different mechanisms. Multiple mechanisms have been proposed to underlie the development and maintenance of neuropathy; however, most pharmacological agents generated from preclinical experiments have failed to alleviate the symptoms of CIPN in the clinic. Further research is necessary to identify the specific mechanisms by which each class of chemotherapeutics induces neuropathy.

Original languageEnglish
Pages (from-to)471-508
Number of pages38
JournalProgress in Molecular Biology and Translational Science
Volume131
DOIs
StatePublished - 2015

Fingerprint

Peripheral Nervous System Diseases
Drug Therapy
Pharmacology
Touch
Sensory Receptor Cells
Vibration
Therapeutics
Hot Temperature
Maintenance
Quality of Life
Pain
Research
Pharmaceutical Preparations

Keywords

  • Chemotherapy Mechanisms Neuropathy Pain Peripheral sensory neuron Paclitaxel Vinca alkaloids Oxaliplatin Cisplatin Bortezomib

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Chemotherapy-induced peripheral neuropathy. / Fehrenbacher, Jill.

In: Progress in Molecular Biology and Translational Science, Vol. 131, 2015, p. 471-508.

Research output: Contribution to journalArticle

@article{bfc1b92e5dd1499eab8510060e7a65d4,
title = "Chemotherapy-induced peripheral neuropathy",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is common in patients receiving anticancer treatment and can affect survivability and long-term quality of life of the patient following treatment. The symptoms of CIPN primarily include abnormal sensory discrimination of touch, vibration, thermal information, and pain. There is currently a paucity of pharmacological agents to prevent or treat CIPN. The lack of efficacious therapeutics is due, at least in part, to an incomplete understanding of the mechanisms by which chemotherapies alter the sensitivity of sensory neurons. Although the clinical presentation of CIPN can be similar with the various classes of chemotherapeutic agents, there are subtle differences, suggesting that each class of drugs might induce neuropathy via different mechanisms. Multiple mechanisms have been proposed to underlie the development and maintenance of neuropathy; however, most pharmacological agents generated from preclinical experiments have failed to alleviate the symptoms of CIPN in the clinic. Further research is necessary to identify the specific mechanisms by which each class of chemotherapeutics induces neuropathy.",
keywords = "Chemotherapy Mechanisms Neuropathy Pain Peripheral sensory neuron Paclitaxel Vinca alkaloids Oxaliplatin Cisplatin Bortezomib",
author = "Jill Fehrenbacher",
year = "2015",
doi = "10.1016/bs.pmbts.2014.12.002",
language = "English",
volume = "131",
pages = "471--508",
journal = "Progress in Molecular Biology and Translational Science",
issn = "1877-1173",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Chemotherapy-induced peripheral neuropathy

AU - Fehrenbacher, Jill

PY - 2015

Y1 - 2015

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is common in patients receiving anticancer treatment and can affect survivability and long-term quality of life of the patient following treatment. The symptoms of CIPN primarily include abnormal sensory discrimination of touch, vibration, thermal information, and pain. There is currently a paucity of pharmacological agents to prevent or treat CIPN. The lack of efficacious therapeutics is due, at least in part, to an incomplete understanding of the mechanisms by which chemotherapies alter the sensitivity of sensory neurons. Although the clinical presentation of CIPN can be similar with the various classes of chemotherapeutic agents, there are subtle differences, suggesting that each class of drugs might induce neuropathy via different mechanisms. Multiple mechanisms have been proposed to underlie the development and maintenance of neuropathy; however, most pharmacological agents generated from preclinical experiments have failed to alleviate the symptoms of CIPN in the clinic. Further research is necessary to identify the specific mechanisms by which each class of chemotherapeutics induces neuropathy.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is common in patients receiving anticancer treatment and can affect survivability and long-term quality of life of the patient following treatment. The symptoms of CIPN primarily include abnormal sensory discrimination of touch, vibration, thermal information, and pain. There is currently a paucity of pharmacological agents to prevent or treat CIPN. The lack of efficacious therapeutics is due, at least in part, to an incomplete understanding of the mechanisms by which chemotherapies alter the sensitivity of sensory neurons. Although the clinical presentation of CIPN can be similar with the various classes of chemotherapeutic agents, there are subtle differences, suggesting that each class of drugs might induce neuropathy via different mechanisms. Multiple mechanisms have been proposed to underlie the development and maintenance of neuropathy; however, most pharmacological agents generated from preclinical experiments have failed to alleviate the symptoms of CIPN in the clinic. Further research is necessary to identify the specific mechanisms by which each class of chemotherapeutics induces neuropathy.

KW - Chemotherapy Mechanisms Neuropathy Pain Peripheral sensory neuron Paclitaxel Vinca alkaloids Oxaliplatin Cisplatin Bortezomib

UR - http://www.scopus.com/inward/record.url?scp=84924597328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924597328&partnerID=8YFLogxK

U2 - 10.1016/bs.pmbts.2014.12.002

DO - 10.1016/bs.pmbts.2014.12.002

M3 - Article

VL - 131

SP - 471

EP - 508

JO - Progress in Molecular Biology and Translational Science

JF - Progress in Molecular Biology and Translational Science

SN - 1877-1173

ER -